Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The objective is to investigate the efficacy and safety of Surufatinib Combine With
Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer.